Now this looks like a bright idea! Let’s actually talk to the ultimate payers and give them some idea what we’re thinking of moving through the development pipeline so that the payers can tell us up front what they might be prepared to pay for.
Filed under: Business strategy, Drug approvals and regulation, Drug development / clinical trials, Health and drug costs, health economics | Comments Off
